 Happy New Year everybody. Welcome back to Investor and Tell. I'm Peter Quasi. The markets are a wonderful place to allow us to connect with people and then reconnect with people and I'm thrilled today to be talking to Thomas Smake from Hemostemics. Tom, you and I first met in about 1998. Yes, it was. You've been in the markets a very long time with a stellar reputation. Thank you Peter. You've put together good deals over the years and you have a large following. It's important that we call out the good people and also name the bad people so good for you. Yeah well as you know you're as good as your last deal in this business and you know fortunately I've come across some some good technologies and put together teams that have succeeded. So Hemostemics is a new story to me. I did my research and I have a ton of questions for you. So let's start. The website says you're a co-founder. The company's been around since 2003 I think 2006. So you've been involved with the company off and on since then. You were out of the company for a bit and now you're back in. How did that happen? So yes I co-founded the company in 2005 when a business partner of mine Roger Bergeson had a heart procedure, a stent operation that went horribly wrong. He flew to Thailand and had his stem cell procedure done. He was patient number 35 of this company. He's an investment banker trained on Wall Street. While he was there the principles of the company expressed their interest in getting the company properly financed. So Roger gave me a call literally from his hospital bed and said, Tom I'm here in Thailand and I need you know I need to talk to you and I said I'm all ears Roger and so he put the principles on the phone. That was November 2005. They flew into Toronto in December 2005. We sat at the Royal York and put the deal together in 48 hours and that was the birth of Hemostemic. A licensee of a company based in Israel Theravitae Limited. We created Theravitae Inc. as the licensee which had a license to all of its technology for North America. Right then the company moved to Calgary in 2012 and you started developing your own intellectual property doing your own R&D. Right what we did was we uh the the the the licensor was spending money faster than we could uh then we could raise it as a licensee. So we we amalgamated with the licensor in 2008 uh ran the company as a private company for for five years, raised it about 10.8 million dollars. Um and then it moved to Calgary in 2012 which is where we raised most of the money from. I stepped back at that point in time and uh you know remained a shareholder. My quick math shows you have roughly four million dollars in cash and treasury. We just raised uh about 4.2 million and paid a number of bills. We have enough runway here for then for certainly for the next 12 months plus. And I went through the management team, the advisory board, and the directors. You truly have an independent group of well-known, well-respected people working for you. This is not a group in anybody's pocket. No this is that was that was job one right came back in as CEO. The first thing you had to do was put build credibility um and so yes I was fortunate to find Peter Lacey as a shareholder uh and and when I explained to him what I thought the uh the accurate picture was he like me uh got very upset. He is how about right right just Lee indignant. Yes well he's the chairman of a service corporation, a company he built from one John Deere dealership uh to 63 company owned stores doing you know profitable doing 1.1 billion in revenue and uh and and you know so he's the seasoned CEO and executive chairman. He agreed to uh to join the board and uh and become the chairman. Um beside him is Dr. Ronnie Hirschman like esteemed cardiologist out of New York. He has been an investor in the company since 2003 when he wrote his first check for just under a million dollars uh when he saw as a cardiologist how ACP affected the hearts of patients suffering from end-stage heart failure. Um beside him is Lauren Swambert uh one of uh the Swambert brothers who uh are you know noted businessmen in uh Grand Prairie Alberta and and uh and the second thing I did was I went and recruited an independent board of advisor so uh Sheila Cops is you know former deputy prime minister of Canada. David Sabushi is the former solicitor general of Ontario and Tim Chang is the former managing director of private equity investment for AIG in Hong Kong uh at all independent uh obviously you know very esteemed individuals in their own right right all all ICDs I believe. Yes right so so now we can talk about the real business of the business uh which is to treat various medical conditions the one that caught my eye was ischemia which is a lack of oxygen in the limbs leading to amputation disease uh infection a lot of bad medical things can happen if you suffer from ischemia a lot of diabetics suffer from ischemia does your product help that situation? Yes that's exactly that's exactly what we treat so ischemia is uh uh reduction in circulation in the circulatory system that can happen in the toes feet and legs of of diabetics it can happen in the lungs of patients suffering from uh you know idiopathic pulmonary hypertension or COPD and it can happen in the heart you know as angina as ischemic cardiomyopathy as dilated cardiomyopathy and as end stage heart failure and we have treated more than 500 patients in the clinics um uh of patients suffering from each of those diseases with significant success and I and that's measured not only by the the results of the 500 patients themselves uh but also by an investigator led phase two clinical trials where we've done uh clinical trials of angina patients clinical trials of ischemic cardiomyopathy patients clinical trials of uh peripheral arterial disease and critical in ischemia patients and and um with again published in the journals uh with you know significant efficacy I have to ask is there any impact upon either the SARS-CoV-2 virus or the resulting uh COVID disease? So it's uh I'm gonna say conservatively yes uh the the proof will be in the next clinical trial uh that that is done in this patient grouping but it um you know if you are reading in the press like I am that you're getting uh you know the patients that are getting COVID that are surviving COVID are having problems breathing problems um with their with their heart um that to me is demonstrative of a level of ischemia that that could be treated with ACP. So it's anecdotal so far now you need to run the data to back it up. It's anecdotal we need to we need to create a clinical trial that is focused on patients that have COVID that have these comorbidities of ischemia in the heart and and lungs and and demonstrates the world that it works. So now I'm interested in the story I'm going to go do some more research. I'd like to talk to you again at the end of your next quarter catch up you know put out 48 press releases this year on financial engineering I can't wait to see what you do in Q1. Thomas Smink from Hemostamics. Thank you very much. Once again back with the company good for you. Peter Clausi signing off from Investor Intel. Thanks for your time.